Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Bongarzoni, A."'
Autor:
Velia Bongarzoni, Dimitar G. Efremov, Robin Foà, Giovanni Del Poeta, Roberta Murru, Stefania Ciolli, Maria Rosa Lanza Cariccio, Francesca Romana Mauro, Maria Ilaria Del Principe, Riccardo Boncompagni, Maria Cantonetti, Agostino Cortelezzi, Giovanni D'Arena, Idanna Innocenti, Francesco Ghio, Patrizia Mondello, Simona Sica, Vincenzo Pitini, Barbara Vannata, Nicola Piccirillo, Giulia Cervetti, Francesco Autore, Gianluigi Reda, Paola Anticoli Borza, Luca Laurenti, Alessandro Gozzetti
Publikováno v:
Leukemia Research. 39:1066-1070
The front-line therapy for CLL young and fit patients is chemo-immunotherapy with fludarabine-cyclophosphamide-rituximab (FCR). FCR regimen results in a significant myelosuppression and high rates of early and late infections especially in elderly pa
Autor:
Maurizio Musso, Nicola Di Renzo, Fortunato Morabito, Antonino Mulè, Emilio Iannitto, Andrea Piccin, Giovanni Franco, Elsa Pennese, Massimo Gentile, Giuseppe Visani, Salvatrice Mancuso, Roberto Marasca, Luigi Rigacci, Rita Fazzi, Pellegrino Musto, Velia Bongarzoni, Alfonso Maria D'Arco, A Augello, Delia Rota-Scalabrini, Antonella Montanini
Publikováno v:
British Journal of Haematology. 153:351-357
To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66 years (range 39-85). Forty-three percent
Autor:
Velia Bongarzoni, Alessandro Andriani, Giovanni D'Arena, Enrico Balleari, Maria Teresa Petrucci, Sara Bringhen, Mario Boccadoro, Pellegrino Musto, Tommaso Caravita, Antonio Palumbo, Tommasina Guglielmelli, Giuseppe Pietrantuono
Publikováno v:
Cancer. 113(7)
BACKGROUND. Bisphosphonates (BPs) are effective in the prevention and treatment of skeletal-related events (SREs) in patients with symptomatic myeloma who are receiving chemotherapy. Recent data also suggest a possible antineoplastic activity of BPs.
Autor:
Andrea Camera, Giulio Giordano, Gianluca Gaidano, Eustachio Miraglia, Davide Rossi, Luciana Annino, Francesco Di Raimondo, Sergio Storti, Giovanni Martinelli, Maide Cavalli, Velia Bongarzoni, Alfredo Gagliardi
Meningeal blastic involvement is a severe complication of aggressive non-Hodgkin lymphoma (NHL) and acute leukemia (AL). DepoCyte® is an unique liposomal formulation for IT administration, that provides a lower toxicity profile and a more convenient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b327a24ff77d25f86a8048869d5ee8
http://hdl.handle.net/20.500.11769/76661
http://hdl.handle.net/20.500.11769/76661
Autor:
Alessandro Gozzetti, Francesca Romana Mauro, Velia Bongarzoni, Mariarita Sciumè, Robin Foà, Francesco Ghio, Patrizia Mondello, Giovanni Del Poeta, Anticoli Borza Paola, Riccardo Boncompagni, Mario Petrini, Nicola Piccirillo, Maria Rosa Lanza Cariccio, Daniele Vincenti, Giovanni D'Arena, Roberta Murru, Agostino Cortelezzi, Vincenzo Pitini, Maria Ilaria Del Principe, Barbara Vannata, Simona Sica, Nadia Cecconi, Luca Laurenti, Stefania Ciolli, F. Autore, Idanna Innocenti, Maria Cantonetti
Publikováno v:
Blood. 124:5655-5655
The front-line therapy for CLL young and fit patients is chemo-immunotherapy with Fludarabine-Cyclophosphamide and Rituximab (FCR). However, around three quarter of the patients with a newly diagnosed CLL are 65 years or older, with approximately 42%
Autor:
Maria Grazia Lipari, Alberto Mussetti, Sergio Storti, Alessandro Andriani, Giuseppe Pietrantuono, Roberto Guariglia, Velia Bongarzoni, Catello Califano, Stefania Tamiazzo, Vincenzo Ludovico Fraticelli, Andrea Nozza, Daniele Derudas, Vittorio Montefusco, Alberto Fragasso, Cristiana Gasbarrino, Giuseppe Mele, Stelvio Ballanti, Giuliana Farina, Maria Carmen Martorelli, Giovanni D'Arena, Antonio Palumbo, Luca Baldini, Maria Pia Petrilli, Donatella Vincelli, Giovanna Mansueto, Antonietta Falcone, Francesca Patriarca, Oreste Villani, Lucio Catalano, Renato Zambello, Emanuela Madonna, Pellegrino Musto
Publikováno v:
Blood. 120:2971-2971
Abstract 2971 Introduction: Bendamustine is a bifunctional alkylating agent approved for the treatment of several lymphoproliferative disorders. Studies have evidenced its efficacy in multiple myeloma (MM), but data so far available in this setting a
Autor:
A. Falcone, A. Palumbo, Alessandra Larocca, C Di Bello, S Morandi, A. Gabbas, Manuela Rizzo, M.T. Petrucci, Velia Bongarzoni, Pellegrino Musto, Elisabetta Calabrese, Robert Foa, Anna Marina Liberati, Federica Cavallo, Vincenzo Callea, Antonio Capaldi, S Bringhen, V. De Stefano, Mario Boccadoro
Publikováno v:
Clinical Lymphoma and Myeloma. 9:S16
Introduction and Aims: New agents have been introduced as induction prior to autologous stem cell transplantation (ASCT) and as consolidation/maintenance thereafter to improve complete response (CR) rates. We evaluate bortezomib plus pegylatedlyposom
Autor:
Paola Anticoli Borza, Velia Bongarzoni, Benedetto Ronci, Barbara Anaclerico, Maria Concetta Petti, Michele Cedrone, Mariangela Vittori, Susanna Fenu, Luciana Annino, Maria Cantonetti, Anna Chierichini
Publikováno v:
Blood. 112:4954-4954
Background. Relapsed/refractory high grade NHL is a very aggressive pathology characterised by a poor prognosis. High dose therapy followed by peripheral blood stem cell (PBSC) rescue is to date the gold standard therapy. The results of high dose the
Autor:
Paola Anticoli Borza, Carolina Nobile, Benedetto Ronci, Susanna Fenu, Luciana Annino, Velia Bongarzoni, Maurizio Bartolini, Barbara Anaclerico, Anna Chierichini, Michele Cedrone
Publikováno v:
Blood. 110:5101-5101
In patients undergoing ASCT, RBC transfusions are depending on donor availability and correlated with early and late side effects such as immune reactions and infections. Three weeks long acting Darbepoietin is currently available, but its role in AS
Autor:
Velia Bongarzoni, Carla Tozzi, Fulivio Pauselli, Barbara Anaclerico, Clara Nervi, Carolina Nobile, Su Ellen Vignetti, Stefania Cortese, Luciana Annino, Anna Chierichini, Giuseppe Cimino, Loredana Bove, Paola Anticoli Borza, Susanna Fenu
Publikováno v:
Blood. 110:4362-4362
Recent reports indicated the clinical feasibility and biological therapeutic potentiality of epigenetic treatments with VPA + ATRA or ATRA alone and suggested the capability of these agents in rendering neoplastic cells more sensitive to chemotherapy